Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Equity Average (2021 - 2025)

Historic Equity Average for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $515.2 million.

  • Kiniksa Pharmaceuticals International's Equity Average rose 1815.03% to $515.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $515.2 million, marking a year-over-year increase of 1815.03%. This contributed to the annual value of $438.6 million for FY2024, which is 506.44% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Equity Average stood at $515.2 million for Q3 2025, which was up 1815.03% from $476.2 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Equity Average ranged from a high of $515.2 million in Q3 2025 and a low of $159.9 million during Q2 2022
  • Moreover, its 5-year median value for Equity Average was $404.6 million (2023), whereas its average is $359.9 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Equity Average crashed by 3687.07% in 2022, and later surged by 15075.25% in 2023.
  • Kiniksa Pharmaceuticals International's Equity Average (Quarter) stood at $199.5 million in 2021, then soared by 95.49% to $390.1 million in 2022, then grew by 8.18% to $422.0 million in 2023, then rose by 3.73% to $437.7 million in 2024, then increased by 17.7% to $515.2 million in 2025.
  • Its last three reported values are $515.2 million in Q3 2025, $476.2 million for Q2 2025, and $448.0 million during Q1 2025.